LHC Group, Inc. (NASDAQ:LHCG): Q3 Non-GAAP EPS of $1.26 beats by $0.18; GAAP EPS of $0.96 misses by $0.12.
Revenue of $528.5M (+4.2% Y/Y) misses by $5.65M.
Wednesday, November 6, 2019
Lannett FQ1 top line down 18% as pricing headwinds continue
Lannett Company (NYSE:LCI) fiscal Q1 results:
Sales: $127.3M (-17.9%).
Net loss: ($12.2M) (+95.8%); non-GAAP net income: $8.8M (-48.2%); loss/share: ($0.32) (+95.8%); non-GAAP EPS: $0.22 (-50.0%).
Fiscal 2020 guidance: Sales: $525M – 545M (unch); non-GAAP EBITDA: $145M – 160M (unch).
Shares down 4% after hours.
Cellular Biomedicine EPS misses by $0.15
Cellular Biomedicine (NASDAQ:CBMG): Q3 GAAP EPS of -$0.82 misses by $0.15.
Cash and equivalents of $29.04M.
Aerie Pharma down 15% after hours as product sales lag
Aerie Pharmaceuticals (NASDAQ:AERI) Q3 results:
Product sales: $18.5M (+153.4%).
Net loss: ($49.4M) (+42.2%); loss/share: ($1.09).
2019 guidance: Revenues: $61M – 66M from $70M – 80M.
Previously: Aerie Pharmaceuticals EPS misses by $0.06, beats on revenue (Nov. 6)
IQiyi +5.2% after 31% subscriber growth in Q3
IQiyi (NASDAQ:IQ) is up 5.2% after hours following its Q3 report, which featured double-digit user growth alongside a slightly wider operating loss.
“Despite a challenging environment, we delivered another quarter of top-line growth with total revenues increasing 7% year-over-year to RMB7.4B,” says CFO Xiaodong Wang.
That was driven by subscription business: Membership services revenue grew 30% to 3.7B yuan; online advertising fell 14% to 2.1B yuan; content distribution fell 18% to 680.4M yuan; and other revenues rose 12T to 932.3M yuan (driven mainly by the game business).
Operating loss swelled to 2.8B yuan from 2.6B yuan, and net loss widened to 3.7B yuan from 3.1B yuan.
Meanwhile, subscribing members rose to 105.8M from 80.7M, a 31% gain. Of subscribers, 99.2% were paying members.
Conference call to come at 7 p.m. ET.
Puma Bio down 12% after hours as Nerlynx sales growth decelerates
Puma Biotechnology (NASDAQ:PBYI) Q3 results:
Revenues: $56.4M (-9.9%); Nerlynx sales: $53.5M (+1.7%).
Net loss: ($16.9M) (-19.0%); non-GAAP net income: ($4.7M) (-171.2%); loss/share: ($0.44) (-18.9%); non-GAAP EPS: ($0.12) (-175.0%).
Cash flow ops (9 mo.): $20.8M (+166.7%).
Shares down 12% after hours.
Previously: Puma Biotechnology EPS beats by $0.33, misses on revenue (Nov. 6)
DexCom Q3 sensor sales up 64%; shares up after hours
DexCom (NASDAQ:DXCM) Q3 results:
Revenues: $396.3M (+48.6%); Sensors & other: $317.2M (+63.5%).
Net income: $45.8M (-1.7%); non-GAAP net income: $60.4M (+279.9%); EPS: $0.50 (-3.8%); non-GAAP EPS: $0.65 (+261.1%).
2019 guidance: Revenues: $1.425B – 1.450B from $1.325B – 1.375B.
Shares up 15% after hours.
Previously: DexCom EPS beats by $0.45, beats on revenue (Nov. 6)
Subscribe to:
Comments (Atom)